SGMT

Sagimet Biosciences Inc. Class A · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website agimet.com
Employees(FY) 9
ISIN US7867001049

Performance

+1.09%

1W

+10.53%

1M

-38.81%

3M

+98.28%

6M

-14.76%

YTD

-71.03%

1Y

Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Advanced Technical Analysis

Technical Analysis of SGMT 2024-05-10

Overview:

In analyzing the technical indicators for SGMT over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the upcoming days.

Trend Analysis:

Moving Averages (MA): The 5-day Moving Average (MA) has been steadily increasing, i...

See more ...

Recent News & Updates

2024-05-15 20:00
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024(Globenewswire)
2024-05-15 00:53
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024(Investorplace)
2024-05-14 20:00
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates(Globenewswire)
2024-05-06 20:00
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024(Globenewswire)
2024-05-05 20:00
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer(Globenewswire)
2024-04-21 20:00
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024(Globenewswire)
2024-03-27 04:01
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat(Globenewswire)
2024-03-24 19:00
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors(Globenewswire)
2024-03-24 18:15
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates(Globenewswire)
2024-02-28 19:00
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences(Globenewswire)
2024-01-25 07:58
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock(Globenewswire)
2024-01-23 04:45
Sagimet Biosciences Announces Proposed Public OfferingÂ of Series A Common Stock(Yahoo Finance)
2024-01-22 10:10
Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH(Prnewswire)
2024-01-21 18:00
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH(Globenewswire)
2023-12-03 19:00
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic(Globenewswire)
2023-11-27 19:00
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit(Globenewswire)
2023-11-21 19:00
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference(Globenewswire)
2023-11-12 19:00
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates(Globenewswire)
2023-11-09 19:30
Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting 2023(Globenewswire)
2023-10-23 23:00
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting 2023(Globenewswire)
2023-10-18 04:05
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference(Globenewswire)
2023-09-27 04:05
Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma(Globenewswire)
2023-08-28 22:21
Load Up, Says Goldman Sachs About These 2 Strong Buy Stocks(Yahoo Finance)
2023-08-21 04:02
Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates(Yahoo Finance)
2023-08-15 04:04
Sagimet Biosciences Announces Closing of Underwriters Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering(Yahoo Finance)
2023-08-07 22:02
DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls(Yahoo Finance)
2023-07-20 04:05
Sagimet Biosciences Announces Leadership Changes(Yahoo Finance)
2023-07-13 09:10
Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering(Yahoo Finance)

Page 1 of 1

previousnext